Puma Biotechnology is a Los Angeles-based developer of biopharmaceuticals aimed at treating cancer. The article describes the company broadly as focused on cancer therapies but does not detail specific drug candidates or programs. In November 2011 the company completed a second tranche of a $60M private financing. Leerink Swann LLC acted as the lead placement agent and National Securities Corporation was the co-placement agent on the transaction. Reported shareholders include Adage Capital Partners, Brookside Capital, H&Q Healthcare Investors, H&Q Life Science Investors, and T. Rowe Price Associates. The article does not provide operating metrics, revenue, or clinical-stage details.

Total raised

$60M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2011